Inbx-106 plus pembrolizumab shows robust first-line HNSCC efficacy
INBRX-106 plus pembrolizumab reported significant improvements in response rate, depth and durability in first-line HNSCC, especially in HPV-positive patients, with manageable safety. Study expansion and accelerated regulatory strategies are underway.
INBRX-106 plus pembrolizumab showed significant improvements in response rate, depth and durability in first-line HNSCC, especially in HPV-positive patients, with manageable safety. Study expansion and accelerated regulatory strategies are underway, targeting a large and growing market.